Nuvectis Pharma, Inc. (NVCT) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-19.51M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.70× | Operating cash flow / net income. Period ending 2026-06-30. $-19.51M ÷ $-27.85M ≈ 0.70× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -19.51M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -27.85M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-19.51M | (m) | (m) | (m) | (m) | $-27.85M | (m) | (m) | (m) | 0.70× |
| 2026-03-31 | (m) | (m) | $-18.35M | (m) | (m) | (m) | (m) | $-27.16M | (m) | (m) | (m) | 0.68× |
| 2025-12-31 | (m) | (m) | $-16.01M | (m) | (m) | (m) | (m) | $-26.44M | (m) | (m) | (m) | 0.61× |
| 2025-09-30 | (m) | (m) | $-14.50M | (m) | (m) | (m) | (m) | $-25.38M | (m) | (m) | (m) | 0.57× |
| 2025-06-30 | (m) | (m) | $-12.41M | (m) | (m) | (m) | (m) | $-22.07M | (m) | (m) | (m) | 0.56× |
| 2025-03-31 | (m) | (m) | $-12.06M | (m) | (m) | (m) | (m) | $-20.16M | (m) | (m) | (m) | 0.60× |
| 2024-12-31 | (m) | (m) | $-12.25M | (m) | (m) | (m) | (m) | $-19.00M | (m) | (m) | (m) | 0.64× |
| 2024-09-30 | (m) | (m) | $-13.63M | (m) | (m) | (m) | (m) | $-19.37M | (m) | (m) | (m) | 0.70× |
| 2024-06-30 | (m) | (m) | $-14.47M | (m) | (m) | (m) | (m) | $-21.10M | (m) | (m) | (m) | 0.69× |
| 2024-03-31 | (m) | (m) | $-15.54M | (m) | (m) | (m) | (m) | $-22.38M | (m) | (m) | (m) | 0.69× |
| 2023-12-31 | (m) | (m) | $-15.95M | (m) | (m) | (m) | (m) | $-22.26M | (m) | (m) | (m) | 0.72× |
| 2023-09-30 | (m) | (m) | $-15.62M | (m) | (m) | (m) | (m) | $-22.33M | (m) | (m) | (m) | 0.70× |
| 2023-06-30 | (m) | (m) | $-16.80M | (m) | (m) | (m) | (m) | $-22.33M | (m) | (m) | (m) | 0.75× |
| 2023-03-31 | (m) | (m) | $-15.26M | (m) | (m) | (m) | (m) | $-20.19M | (m) | (m) | (m) | 0.76× |
| 2022-12-31 | (m) | (m) | $-13.56M | (m) | (m) | (m) | (m) | $-19.09M | (m) | (m) | (m) | 0.71× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $-9.50M | (m) | (m) | (m) | (m) | $-12.89M | (m) | (m) | (m) | 0.74× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |